Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1025 | 1061 | 1060 | 1111 | 1381 | 1904 |
Fund Return | 2.54% | 6.09% | 6.03% | 3.57% | 6.67% | 6.65% |
Place in category | 228 | 129 | 132 | 325 | 112 | 46 |
% in Category | 32 | 19 | 22 | 60 | 26 | 17 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pictet CH Institutional Swiss EquiI | 1.73B | 11.30 | 1.45 | 7.20 | ||
Pictet CH Institutional Swiss EquiP | 1.73B | 11.13 | 1.25 | 6.99 | ||
Pictet CH Institutional Swiss EquiZ | 1.73B | 11.68 | 1.93 | 7.71 | ||
Pictet CH Institutional Swiss EquZD | 1.73B | 6.53 | -1.03 | 7.24 | ||
Pictet CH Swiss Mid Small Cap Z dy | 1.42B | 5.51 | -1.91 | 9.57 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.35B | 9.28 | 2.17 | 6.28 | ||
Raiffeisen Futura Swiss Stock A | 2.17B | 7.92 | -0.59 | 6.39 | ||
UBS CH Equity Fund Swiss Income CHQ | 2.05B | 2.59 | 4.20 | 6.41 | ||
UBS CH Equity Fund Swiss Income CHF | 2.05B | 2.43 | 3.56 | 5.81 | ||
Pictet CH Institutional Swiss EquiI | 1.73B | 11.30 | 1.45 | 7.20 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Nestle | CH0038863350 | 15.83 | 78.00 | -1.29% | |
Roche Holding Participation | CH0012032048 | 11.15 | 262.50 | -1.13% | |
Novartis | CH0012005267 | 10.16 | 92.36 | -0.78% | |
Zurich Insurance Group | CH0011075394 | 5.31 | 515.00 | -1.68% | |
ABB | CH0012221716 | 5.30 | 49.50 | -2.29% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Sell | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Strong Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review